Evidence map›Paper›PMID 37012462›Full record

ArticleAnnals of hematology2023

Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.

Johannes Lübke, Nicole Naumann, Georgia Metzgeroth, Sebastian Kreil, Timo Brand, Hans-Peter Horny, Karl Sotlar, Nicholas C P Cross, Alice Fabarius, Peter Valent and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Johannes LübkeDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0767-1504
Nicole NaumannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Georgia MetzgerothDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Sebastian KreilDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Timo BrandDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Hans-Peter HornyDepartment of Pathology, Ludwig-Maximilians-University, Munich, Germany.
Karl SotlarDepartment of Pathology, Paracelsus Medical University of Salzburg, Salzburg, Austria.
Nicholas C P CrossFaculty of Medicine, University of Southampton, Southampton, UK.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Peter ValentDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Andreas Reiter *Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. andreas.reiter@medma.uni-heidelberg.de.
Juliana Schwaab *Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Heidelberg University · DELudwig-Maximilians-Universität München · DEMedical University of Vienna · ATUniversity of Salzburg · ATUniversity of Southampton · GB

Funding

Austrian Science Fund SFB F4704-B20José Carreras Leukämie-Stiftung DJCLS 08R/2020
6 · The paper itself

Abstract

We sought to evaluate the efficacy of the purine analogue cladribine in 79 patients with advanced systemic mastocytosis (AdvSM) using data from the 'German Registry on Disorders of Eosinophils and Mast Cells (GREM)'. The overall response rate according to modified Valent criteria (46 evaluable patients) for first- (1L) and second-line (2L) cladribine treatment was 41% (12/29) and 35% (6/17, P = 0.690), respectively, and the median overall survival (OS, all patients evaluable) was 1.9 years (n = 48) and 1.2 years (n = 31; P = 0.311). Univariate and multivariable analyses of baseline and on-treatment parameters identified diagnosis of mast cell leukemia (hazard ratio [HR] 3.5, 95% confidence interval [CI, 1.3-9.1], P = 0.012), eosinophilia ≥ 1.5 × 10

Indexed as

Leukemia, Mast-CellMastocytosis, SystemicCladribineHumansPrognosisRegistriesCladribineAdvanced systemic mastocytosisChemotherapyCladribinePurine analogue

Identifiers

PMID37012462
PMCPMC10344834
OpenAlexW4362522094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.